Risperidone augmentation of selective serotonin reuptake inhibitors in major depression

Journal of Clinical Psychiatry

Volumn 60, Issue 4, 1999, Pages 256-259

  Ostroff, Robert B ^a,b   Nelson, J Craig ^b  

^a Spectrum Psychiatric Group   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RISPERIDONE; SEROTONIN UPTAKE INHIBITOR;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DEPRESSION; DRUG POTENTIATION; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; REMISSION; SCORING SYSTEM; SEXUAL DYSFUNCTION; SLEEP DISORDER;

EID: 0032910369     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v60n0410     Document Type: Article

References (16)

1. Clinical Practice Guideline Number 5: Depression in Primary Care, vol 2. Treatment of Major Depression. Rockville, Md: US Dept Health Human Services, Agency for Health Care Policy and Research; 1993. AHCPR publication 93-0551
2. Nelson JC. Augmentation strategies for treatment of unipolar major depression. In: Rush AJ, ed. Mood Disorders: Systematic Medication Management. Modern Problems of Pharmacopsychiatry, vol 25. Basel, Switzerland: S Karger; 1997:34-55
3. Thase ME, Rush AJ. Treatment-resistent depression. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 1995
4. Borison RL, Pathiraja AP, Diamond BI, et al. Risperidone: clinical safety and efficacy in schizophrenia. Psychopharmacol Bull 1992;28:213-218
5. Lakoski JM, Aghajanian GK. Effects of ketanserin on neuronal responses to serotonin in the prefrontal cortex, lateral geniculate and dorsal raphe nucleus. Neuropharmacology 1985;24:265-273
6. Fontaine R, Ontiveros A, Elie R, et al. A double-blind comparison of nefazodone, imipramine, and placebo in major depression. J Clin Psychiatry 1994;55:234-241
7. Rickels K, Schweizer E, Clary C, et al. Nefazodone and imipramine in major depression: a placebo-controlled trial. Br J Psychiatry 1994;164: 802-805
8. Blackburn TP. 5-HT receptors and anxiolytic drugs. In: Marsden CA, Heal DJ, eds. Central Serotonin Receptors and Psychotropic Drugs. London, England: Blackwell Scientific Publications; 1992:39-55
9. 2) mediation of anxiety-therapeutic effects of serazepine in generalized anxiety disorder. Biol Psychiatry 1993;34:41-44
10. Nelson JC. The use of antipsychotic drugs in the treatment of depression. In: Zohar J, Belmaker RH, eds. Treating Resistant Depression. New York, NY: PMA Publishing; 1987
11. Claus A, Bollen J, De Cuyper H, et al. Risperidone vs haloperidol in the treatment of chronic schizophrenic inpatients: a multicenter double-blind comparative study. Acta Psychiatr Scand 1992;85:295-305
12. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
13. Nelson JC, Mazure CM, Jatlow PI. Characteristics of desipramine-refractory depression. J Clin Psychiatry 1994;55:12-19
14. Janicak PG, Pandey GN, Davis JM, et al. Response of psychotic and nonpsychotic depression to phenelzine. Am J Psychiatry 1988;145:93-95
15. Feiger A, Kiev A, Shrivastava RK, et al. Nefazodone versus sertraline in outpatients with major depression: focus on efficacy, tolerability, and effects on sexual function and satisfaction. J Clin Psychiatry 1996;57 (suppl 2):53-62
16. Gillin JC, Rapaport M, Erman MK, et al. A comparison of nefazodone and fluoxetine on mood and on objective, subjective, and clinician-rated measures of sleep in depressed patients: a double-blind, 8-week clinical trial. J Clin Psychiatry 1997;58:185-192. Correction 1997;58:275